Quick Takeaways:
- Innocan Pharma Corporation announced publication of clinical data in Frontiers in Veterinary Science showing its liposomal CBD (LPT-CBD) delivered significant improvements in pain and mobility in dogs with osteoarthritis vs. placebo.
- In the randomized crossover study, 100% of dogs showed functional improvement (vs. 25% placebo), along with reduced lameness and pain, while maintaining a sustained-release profile lasting up to 4 weeks from a single injection.
- LPT-CBD was well tolerated with only mild, transient side effects, and its long-acting profile positions it as a promising alternative for chronic pain management, with ongoing discussions underway with the US FDA to advance development.
Why It Matters?
Data for LPT‑CBD strengthens the scientific case for long‑acting, injectable CBD as a legitimate chronic pain option, not just a wellness supplement, which can increase veterinarian openness to cannabinoid-based therapies.
The sustained 4‑week effect from a single injection and favorable safety profile position LPT‑CBD as a convenient, compliance‑friendly alternative or add‑on to NSAIDs, especially for dogs that cannot tolerate oral therapies, supporting Innocan’s ongoing regulatory discussions with FDA CVM.
Source: PRnewswire
